ATOS Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 -11.12%, SMA50 -43.47%, SMA200 -61.36%). The stock’s 14-day RSI is 32.11 (weak momentum), while the ATR of 0.58 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -76.9% below its high and over 18.88% above its low. Average 10-day trading volume of 73.55 thousand shares is below the 3-month average of 133.40 thousand, indicating normal recent market interest.

Atossa Therapeutics, Inc. generated EPS of -$3.52 over the past year. Five-year average earnings growth is 36.92%. Wall Street analysts project EPS growth of -16.39% annually over the next five years. The latest quarter delivered EPS of -$0.07. The next quarter is forecast at -$1.14. Next year's EPS is expected at -$8.16. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $8.00 to $4.00. The high target offers 42.6% upside. The low target suggests -28.7% downside. The mean target is $6.69. This offers 19.25% upside. Atossa Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by -3.87%. The prior quarter beat by 16.67%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in August 12, 2024.

Atossa Therapeutics, Inc. has 8.61 million shares outstanding. The public float is 8.61 million shares, elevated short interest at 4.74% of float. This equals 361.04 thousand shares. The short ratio is 1.86 days. Institutional investors hold 19.46% of the float. Insiders own 0.07%. CROSS ALEXANDER D holds 88.87 thousand shares, Finn Jonathan has 25.00 thousand shares and QUAY STEVEN C has 13.90 thousand shares.

Atossa Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $8.47. This means the shares are trading below this model’s fair value.

Atossa Therapeutics, Inc. (NASDAQ:ATOS) closed at $5.51 USD, losing -$0.10 (-1.78%) from the previous close of $5.61. The stock is currently mid-range between its 52-week high and low $3.76 and $19.35. With a market capitalization of about $47.45 million, Atossa Therapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.49). Key stats such as the average daily volume over the past year has been around 146.10 thousand shares, volume is running light vs its 52-week average. Headquartered in Seattle, WA, Atossa Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Steven C. Quay, the company employs approximately 15 people and listed since November 08, 2012. Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States.

Atossa Therapeutics, Inc. trades at a P/E ratio of -1.59, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.96 suggesting the stock is closer to book value. The P/FCF stands at -1.82, also below market averages.

Atossa Therapeutics, Inc. (NASDAQ:ATOS) shares are flat 2.2% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Atossa Therapeutics, Inc. trading at a premium to the broader market with a P/E of -1.59. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $6.15, suggesting 9.63% upside. Our AI forecast model points to short-term weakness (-11.05% over two weeks), a medium-term rise (8.73% over three months), and a longer-term loss (-34.76% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Atossa Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -11.05%, with price expected at $4.99 by April 06, 2026, within a range of $3.75 to $6.22 3-Month Outlook: Projected rise of 8.73%, reaching $6.10 by June 19, 2026, with a range of $5.51 to $6.56. 1-Year Outlook: Projected loss of -34.76%, with price at $3.66 by March 23, 2027, within a range of $0.00 to $0.46.